EyePoint reports favorable 6-month results for Duravyu in Phase 2 trial for DME
EyePoint Pharmaceuticals announced positive 6-month results from its Phase 2 VERONA clinical trial of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME). The investigational therapy demonstrated significant improvements in both best-corrected visual acuity (BCVA) and central subfield thickness (CST) compared to the aflibercept control group. Specifically, patients receiving Duravyu 2.7 mg experienced an average gain of 8.9 letters in BCVA and a 68.1-micron reduction in CST, while the aflibercept group showed gains of 3.2 letters and a 30.5-micron reduction, respectively.
The therapy also exhibited a favorable safety profile, with no serious adverse events related to Duravyu reported.
Full topline data from the trial is expected in the first quarter of 2025.
Read the full press release here.
Related Content
